



		ATTY. DOCKET NO.:	APPLICATION NO.:
		87754-7500	10/644/687
APPLICANT:			
Haim AVIV et al.			
FILING DATE:	GROUP:		
August 19, 2003	1614 / 1626		

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS							
cont....							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AC						
	AD						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
YD	AE	Mechoulam R. and Hanuš L., "A Historical Overview Of Chemical Research On Cannabinoids", Chem. Phys. Lipids, Vol. 108, pp. 1-13 (2000). ✓
	AF	Mechoulam R. et al., "Synthesis Of The Individual, Pharmacologically Distinct, Enantiomers Of A Tetrahydrocannabinol Derivative", Tetrahedron Asymmetry, Vol. 1, No. 5, pp. 315-318, (1990). ✓
	AG	Ottani A. et al., "HU-210: A Potent Tool For Investigations Of The Cannabinoid System", CNS Drug Reviews, Vol. 7, No. 2, pp. 131-145, (2001). ✓
	AH	Levin S. et al. "Resolution Of Chiral Cannabinoids On Amylose Tris(3, 5-dimethylphenylcarbamate) Chiral Stationary Phase: Effects Of Structural Features And Mobile Phase Additives", Journal of Chromatography A., Vol. 654, pp.53-64, (1993). ✓
	AI	Pop E. et al, "Derivatives Of Dexanabinol I. Water-Soluble Salts Of Glycinate Esters", Pharmaceutical Research, Vol. 13, pp. 62-69, (1996). ✓
	AJ	Pop E. et al., "Derivatives Of Dexanabinol II. Salts Of Amino Acid Esters Containing Tertiary And Quaternary Heterocyclic Nitrogen With Increased Water-Solubility", Pharmaceutical Research, Vol. 13, pp469-475, (1996). ✓
	AK	Pop E. et al. "In Vitro And In Vivo Study Of Water-Soluble Prodrugs Of Dexanabinol", Pharmaceutical Research Sciences, Vol. 88, pp. 1156-1160, (1999) ✓
	AL	Pop E. et al, "Water-Soluble Combinations Of Dexanabinol: Prodrugs And Analogs", Pharmazie, Vol. 55, pp 167-171, (2000) ✓
	AM	Thomas B.F. et al., "Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency", Journal Pharmacology and Experimental Therapeutics, Vol.. 255, pp. 624-630, (1990). ✓

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
YD	AN	Brewster M. E. et al, "Clinical Pharmacokinetics Of Escalating i.v. Doses Of Dexanabinol (HU-211), A Neuroprotectant Agent, In Normal Volunteers", International Journal Of Clinical Pharmacology and Therapeutics, Vol. 35, pp.: 361-365, (1997) ✓
✓	AO	Knoller N. et al, "Dexanabinol (HU-211) In The Treatment Of Severe Closed Head Injury: A Randomized, Placebo-Controlled, Phase II Clinical Trial" Crit. Care Med., Vol 30, pp. 548-554, (2002) ✓
	AP	
	AQ	
	AR	
	AS	
EXAMINER		DATE CONSIDERED
<i>T. A. Sola</i>		<i>4/18/05</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		